A Myovant Sciences Ltd. investor wants an appellate court to rehear allegations of a conflict of interest that warranted disclosure when Skadden, Arps, Slate, Meagher & Flom LLP advised on its 2022 buyout deal.
The US Court of Appeals for the Second Circuit last month affirmed dismissal with prejudice of Joseph Zappia’s lawsuit, finding alleged ties between the acquirer Sumitovant Biopharma Ltd. and Sumitomo Mitsui Banking Corp., which Skadden represented in other matters, “too attenuated.” The plaintiff petitioned Thursday for reconsideration of the court’s opinion denying his request for leave to amend, claiming the panel overlooked information from ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.